Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dual Arm Factorial Randomized Trial in Patients w/ST Segment Elevation AMI to Compare the Results of Using Anticoagulation With Either Unfractionated Heparin + Routine GP IIb/IIIa Inhibition or Bivalirudin + Bail-out GP IIb/IIIa Inhibition; and Primary Angioplasty With Stent Implantation With Either a Slow Rate-release Paclitaxel-eluting Stent (TAXUS) or Uncoated Bare Metal Stent (EXPRESS2)

Trial Profile

Dual Arm Factorial Randomized Trial in Patients w/ST Segment Elevation AMI to Compare the Results of Using Anticoagulation With Either Unfractionated Heparin + Routine GP IIb/IIIa Inhibition or Bivalirudin + Bail-out GP IIb/IIIa Inhibition; and Primary Angioplasty With Stent Implantation With Either a Slow Rate-release Paclitaxel-eluting Stent (TAXUS) or Uncoated Bare Metal Stent (EXPRESS2)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 15 Dec 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bivalirudin (Primary) ; Paclitaxel (Primary) ; Abciximab; Eptifibatide; Heparin; Tirofiban
  • Indications Coronary artery restenosis; Myocardial infarction; Stent thrombosis; Thrombosis
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms HORIZONS-AMI; HORIZONS-AMI CMRI
  • Most Recent Events

    • 07 Nov 2022 Results of pooled subgroup analysis (n=15254) assessing efficacy of bivalirudin versus heparin in patients with STEMI undergoing PCI from BRIGHT, EUROMAX, HEAT-PPCI, HORIZONS-AMI, MATRIX, and VALIDATE-SWEDEHEART studies, presented at the American Heart Association Scientific Sessions 2022.
    • 01 Dec 2017 Results of age-based subgroup analysis assessing the effect of bivalirudin versus heparin using 30-day pooled data (n=5800) from the two large randomized trials (EUROMAX and HORIZONS-AMI), published in the American Heart Journal.
    • 29 Mar 2017 Results of comparison of outcomes and prognostic factor in patients with versus without newly diagnosed daibetes mellitus published in the American Journal of Cardiology
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top